Skip to main content
UniHealth

Doctor search

Saisindhu Narala, MD

Dermatology · Stanford

NPI 1205368008

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
13
2 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Narala’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A172013 · Current

Licensed to practise in California · since 2021 · expires 2027-03-31 · University of California, San Diego School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$52,041

Medicare paid this office $52,041 for 307 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)97$14,778$87
Short return visit (20+ min)153$11,668$58
Destruction of skin growth, 1-14 growths65$5,520$64
Destruction of precancer skin growth, 1 growth81$4,218$43
New patient visit (45+ min)39$4,033$103
See all 15 services
Every Original Medicare service billed
Return visit (30+ min)97$14,778$87
Short return visit (20+ min)153$11,668$58
Destruction of skin growth, 1-14 growths65$5,520$64
Destruction of precancer skin growth, 1 growth81$4,218$43
New patient visit (45+ min)39$4,033$103
New patient visit (30+ min)50$3,611$72
Biopsy of related skin growth, first growth64$1,666$23
Destruction of precancer skin growth, 15 or more growths12$1,433$90
Biopsy of related skin growth, each additional growth23$678$20
Injection into skin growth, 1-7 growths12$625$23
New patient visit (15+ min)11$492$45
Punch biopsy, first skin growth13$462$33
Destruction of precancer skin growth, 2-14 growths63$355$2
Short return visit11$268$24
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's16$254$15

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions528More than 87% of doctors who do this
Removal or shaving of skin growth1-10None
Skin biopsy176More than 83% of doctors who do this

Who their Medicare patients are

307 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 12% · Women 60% · Also on Medicaid 24% · Health risk score 1.21. Above the middle of the specialty; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 64% · Diabetes 26% · Chronic kidney disease 22% · Coronary heart disease 17% · Cancer 15% · Atrial fibrillation 15% · Heart failure 14% · Depression 14% · COPD 10% · Stroke 9% · Dementia 5%.

The office billed $225,587, Medicare allowed $70,626 and paid $52,041; for 1,067 services of 25 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243071,067731.21$225,587$52,041
2023249823721.39$163,526$36,273
202272161681.54$32,276$6,997

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 12 services

Original Medicare services billed in 2023
Short return visit (20+ min)122$9,421$57
Return visit (30+ min)43$6,146$83
New patient visit (30+ min)69$4,614$67
New patient visit (45+ min)32$3,723$116
Destruction of precancer skin growth, 1 growth58$3,407$45
Destruction of skin growth, 1-14 growths39$3,213$63
Biopsy of related skin growth, first growth40$1,164$25
Injection into skin growth, 1-7 growths15$773$24
Biopsy of related skin growth, each additional growth13$645$21
Punch biopsy, first skin growth11$532$41
Short return visit18$530$28
Destruction of precancer skin growth, 2-14 growths39$360$2

2022: 4 services

Original Medicare services billed in 2022
Short return visit (20+ min)29$1,808$60
New patient visit (30+ min)18$1,259$70
Destruction of precancer skin growth, 1 growth15$697$46
Short return visit13$421$32

Medicaid work

$2,607 in 2024

Medicaid paid $2,607 for 41 billed services this clinician did in 2024, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)41$2,607
Medicaid work by year
202441113$2,607

Drugs they prescribed that Part D paid

$501,272

Pharmacies billed $501,272 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 671) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

573 generic and 98 brand-name prescriptions · $501,272 in drug cost · 20 antibiotic prescriptions to 15 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Dupixent40$137,582$3,440
Dupixent12$40,363$3,364
Fluocinonide57$1,801$32
Ketoconazole102$1,725$17
Tacrolimus17$1,457$86
See all 19 drugs
Every Part D drug this clinician prescribed
Dupixent40$137,582$3,440
Dupixent12$40,363$3,364
Fluocinonide57$1,801$32
Ketoconazole102$1,725$17
Tacrolimus17$1,457$86
Fluorouracil18$1,389$77
Isotretinoin16$1,188$74
Halobetasol Propionate12$1,046$87
Betamethasone Diprop Augmented12$878$73
Clobetasol Propionate27$875$32
Dapsone12$636$53
Triamcinolone Acetonide59$575$10
Doxycycline Hyclate18$544$30
Ciclopirox13$479$37
Clindamycin Phosphate14$289$21
Ciclopirox14$161$11
Mupirocin13$102$8
Hydrocortisone21$73$3
Finasteride12$65$5

Year by year

Part D prescribing by year
20246711830% (0)15%$501,272
20235731630% (0)12%$243,500
202292490% (0)None$61,473
202134210% (0)0%$1,568
2020189830% (0)13%$130,234
2019185890% (0)8%$22,627
2018160540% (0)None$10,749
201778260% (0)None$4,546

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 15 drugs

Part D drugs prescribed in 2023
Dupixent27$105,299$3,900
Otezla16$78,392$4,900
Clobetasol Propionate31$1,945$63
Ketoconazole64$1,594$25
Fluocinonide30$1,419$47
Betamethasone Diprop Augmented17$993$58
Betamethasone Dipropionate15$962$64
Doxycycline Hyclate19$856$45
Triamcinolone Acetonide75$773$10
Fluorouracil13$761$59
Ciclopirox26$466$18
Nystatin17$401$24
Hydrocortisone29$193$7
Fluconazole16$160$10
Mupirocin15$159$11

2022: 1 drug

Part D drugs prescribed in 2022
Triamcinolone Acetonide15$241$16

2020: 5 drugs

Part D drugs prescribed in 2020
Tacrolimus21$17,935$854
Clobetasol Propionate13$686$53
Fluocinonide11$642$58
Triamcinolone Acetonide23$466$20
Ketoconazole12$284$24

2019: 7 drugs

Part D drugs prescribed in 2019
Tacrolimus11$4,729$430
Fluorouracil11$1,532$139
Metronidazole12$1,168$97
Fluocinonide12$1,047$87
Doxycycline Monohydrate17$1,023$60
Ketoconazole13$474$36
Triamcinolone Acetonide22$421$19

2018: 2 drugs

Part D drugs prescribed in 2018
Atorvastatin11$345$31
Pantoprazole12$317$26

Money from drug and device companies

$100 in 2022

A payment is not proof that care is biased.

Payments by company
AbbvieRinvoq$77
1 payment
  • Meals for Rinvoq · 2022-03-26 · $77
PfizerCibinqo$24
1 payment
  • Meals for Cibinqo · 2022-03-27 · $24
See all 2 published payments
Every published payment
PfizerMeals · 2022-03-27Cibinqo$24
AbbvieMeals · 2022-03-26Rinvoq$77

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1205368008
Licence
CA A172013California A172013: Current · expires 2027-03-31
Trained
University of California, San Diego School of Medicine, 2017
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2017-03-30
NPI last updated
2024-04-16
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.